AC Immune SA announced a strategic realignment following a review by executive management, which concluded on September 4, 2025. The company will sharpen its investment focus on its three clinical-stage active immunotherapy programs, two of which are in ongoing pharmaceutical collaborations, and its most promising small molecule programs targeting NLRP3 and Tau.
As a direct result of this strategic review, AC Immune implemented a workforce reduction of approximately 30 employees. This operational adjustment is projected to extend the company's cash runway to the end of the third quarter of 2027.
As of June 30, 2025, AC Immune reported cash resources of CHF 127.1 million, which were previously expected to fund operations into the first quarter of 2027, excluding potential milestone payments. The workforce reduction provides crucial financial stability, allowing the company to advance its key pipeline assets through clinical milestones without immediate pressure for additional dilutive financing. Near-term clinical milestones remain unchanged.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.